Novo Nordisk: FDA OKs label update for Rybelsus® (semaglutide) use as first-line option

 

• People living with type 2 diabetes can now take Rybelsus^®, the first and only oral glucagon-like peptide-1 (GLP-1) analog, along with diet and exercise, as initial therapy to help lower their A1C^1,2
• Since its approval, Rybelsus^® has been prescribed to hundreds of thousands of patients to help improve glycemic control along with diet and exercise

https://www.biospace.com/article/releases/novo-nordisk-announces-fda-approval-of-label-update-for-rybelsus-semaglutide-allowing-use-as-a-first-line-option-for-adults-with-type-2-diabetes/